The Recall Desk
ModerateFDA (Devices)·Z-1406-2014·Announced 2014-04-16

LumiQuick Clonazepam Test Card Recalled for Unapproved Distribution

LumiQuick Diagnostics is recalling Clonazepam Test Cards because they were shipped to US locations without approved PMA, IDE, or 510(k) clearance.

What this means for you

Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.

Our severity reasoning: The recall is classified as FDA Class II, and the hazard involves regulatory non-compliance (unapproved distribution) rather than a direct physical injury or high-risk pathogen, fitting the Moderate criteria for minor labeling or regulatory issues.

Plain-English summary

LumiQuick Diagnostics Inc. is recalling Clonazepam Test Cards (Catalog number 74060, all lots) because the products were shipped to US locations that do not have approved applications for PMA, IDE, or 510(k) clearance.

The recall affects all lots of the product. Distribution was limited to the states of California, Florida, New Jersey, Texas, and New York.

Consumers and healthcare providers should stop using the affected test cards and contact the manufacturer for further instructions.

The recalled product

Product
Clonazepam Test Card; LumiQuick,. Santa Clara, CA 95054

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (2)

  • Catalog number: 74060
  • All lots

Distribution

Distributed in 5 states:

Part of a larger recall action

This product is one of 80 recalled by LumiQuick Diagnostics Inc. under a single FDA (Devices) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.

See all 80 products in this recall →

Same manufacturer · LumiQuick Diagnostics Inc.

See all →